There are 15,358 results relating to "Medicin Viagra-m"
Order by
|
Official Report
Meeting date:
5 September 2024
Meeting of the Parliament 05 September 2024
That is why we are investing in the likes of the Scottish graduate entry medicine programme, so that more rural GPs come through the system, and why we are investing, through the contract, in multidisciplinary teams to ensure that we have a more sustainable general practice position, including in areas in the Highlands and Islands.
Last updated:
2 April 2024
PB_2022_070
S6M-03233: Colette Stevenson: Access to Cannabis-based Products for Medicinal Use - That the Parliament welcomes the Home Office’s rescheduling of certain cannabis-based products for medicinal use (CBPMs) in 2018; notes the reported improvement in some children with treatment resistant epilepsy who take CBPMs, such as Cole Thomson, from East Kilbride, who it understands receives Bedrolite on private prescription; acknowledges the reported financial pressure that these prescriptions can place on families; further acknowledges the reported hesitancy of NHS consultants to prescribe unlicensed CBPMs due to the lack of robust evidence; notes the view that the rescheduling does not go far enough in assisting some patients, and the calls for a change in rules to allow GPs, who consider it appropriate, to prescribe unlicensed CBPMs where a non-NHS consultant has initiated that course of treatment; understands that the British Paediatric Neurology Association published its updated Guidance on the use of cannabis-based products for medicinal use in children PB/S6/22/70 and young people with epilepsy in October 2021, which, it considers, outlines concerns around the lack of randomised control trials demonstrating a product’s safety, quality and efficacy; acknowledges the Scottish Government’s reported commitment to collaborate with NHS England and the National Institute for Health Research to support research trials into medicinal cannabis in order to give NHS consultants the assurances that they need to consider prescribing CBPMs on the NHS; understands that, once a medicinal product has undergone clinical trials, it could be considered by the Medicines and Healthcare products Regulatory Agency for licensing and that this could lead to further consideration by organisations such as the National Institute for Health and Care Excellence, the Scottish Medicines Consortium and NHS Scotland; notes the calls for industry to run observational and clinical trials; believes that an increased evidence base offers the best opportunities for expansion of the range of CBPMs available from the NHS; welcomes the reported plans by Target Healthcare, which operates in East Kilbride, to produce CBPMs in Scotland, and notes the calls on the Scottish and UK governments to work together to find solutions on these issues.
Questions and Answers
Date answered:
23 September 2025
S6W-40250
This is because there was no central system for recording which medicines were prescribed for individuals available at that time and individual paper medical records from this period are unlikely to be retrievable which would make any such exercise extremely challenging.
Questions and Answers
Date answered:
16 April 2024
S6W-26392
To ask the Scottish Government on how many occasions the treatment Olaparib has been prescribed in each NHS board area since it was approved for use by the Scottish Medicines Consortium (SMC) in 2021. Neither the Scottish Government nor Public Health Scotland (PHS) hold this information centrally.
Questions and Answers
Date answered:
12 December 2023
S6W-23380
I have Ministerial portfolio responsibility for access to new medicines in Scotland. Accordingly, as you know, I met with you on 6 December 2023 together with representatives of Scottish cystic fibrosis (CF) families to listen to their concerns directly.
Questions and Answers
Date answered:
19 September 2023
S6W-19959
We are currently in discussion with clinicians including members of the Scottish Strategic Network for Genomic Medicine and the Clinical Genetics Forum to bring together all stakeholder specialities to advise on testing, screening and management for individuals at increased risk of cancer.
Questions and Answers
Date answered:
15 June 2023
S6W-18562
To ask the Scottish Government how many doctors, who qualified through the Scottish Graduate Entry Medicine (ScotGEM) programme, have taken up posts within NHS Dumfries and Galloway since the programme was established.
Questions and Answers
Date answered:
30 September 2021
S6W-02332
Scottish Government officials have had informal discussions with the manufacturer, Gilead Sciences, to provide early access to sacituzumab govitecan (Trodelvy ® ) on an individual patient case by case basis in line with standard processes for such circumstances before it is submitted to the Scottish Medicines Consortium for health technology assessment.
Questions and Answers
Date answered:
14 September 2021
S6W-02621
Our NHS Recovery Plan and Programme for Government commits to investing in developing new digital solutions such as ePrescribing and eDispensing to make the prescribing process paperless which will free up capacity for healthcare professionals so that they can see more patients and making it easier for patients to access their medicines quickly and safely. ...
Questions and Answers
Date answered:
29 July 2021
S6W-01065
Public Health Scotland published data does not provide details on reason for prescribing a specific medicine. S6W-01065
